News

Experts discussed challenges with treating relapsed or refractory diffuse large B-cell lymphoma.

The assistant professor of medicine from Medical College of Wisconsin discussed the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

AVROBIO shared interim safety data from ongoing phase 1 and 2 trials.

The professor of medicine at Washington University School of Medicine in St. Louis discussed the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.

Tofersen failed to meet its primary end point in change from baseline in ALSFRS-R but differences in total cerebrospinal fluid SOD1 protein and neurofilament light chain were observed.

The patient’s daily insulin requirement went from 34 units a day at baseline to 2.9 units a day 90 days after treatment.

The director of the Powell Gene Therapy Center at the University of Florida discussed improving access to gene therapies for patients with rare diseases worldwide.

More than 70% to 80% of homozygous knockout of a given gene can be achieved by electroporating CLL cells with ribonucleoprotein complexes that harbor recombinant Cas9 nuclease and synthetic guides.

The chief of oncology and hematology at University of Nebraska Medical Center discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.

The hematology and medical oncologist at Moffitt Cancer Center discussed results from the phase 1b/2 CARTITUDE-1 trial of cita-cel in R/R MM.

Updated data from the phase 1 TRANSCEND-CLL-004 trial were presented at the International Workshop on CLL.

4D Molecular Therapeuitcs plans to initiate a phase 1/2 trial of 4D-150 before the end of the year.

The associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.

Results from a phase 1/2 study from Nanoscope Therapeutics were presented at the 2021 ASRS meeting.

The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.

Review top news and interview highlights from the week ending October 15, 2021.

Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.

The study follows Legend Biotech’s initial success with cilta-cel, whose PDUFA date is set for November 2021.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed therapies the company is developing.

The cell therapy yielded improvements in visual acuity and central corneal thickness.

The professor from The University of Texas MD Anderson Cancer discussed the impact that brexucabtagene autoleucel's approval has had on mantle cell lymphoma.

Enrollment in the CARBON trial has so far focused on aggressive disease such as diffuse B-cell lymphoma.

New human gene editing therapies, drug discoveries, targets, and CRISPR technology holds the potential to usher in a new age in medicine.

The assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.

REGENXBIO previously announced positive data in patients with wet AMD who were treated with the same gene therapy.

Sarepta Therapeutics has also initiated the pivotal phase 3 EMBARK study in pediatric patients with DMD.

Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s technology and focus on mRNA therapies.

Intellia Therapeutics is also initiating a phase 1/2 study of a CRISPR therapy for hereditary angioedema in New Zealand.